Influence of dose rate on radiotherapy treatment of the U87MG cell line through cell viability
DOI:
https://doi.org/10.15392/2319-0612.2024.2621Palabras clave:
Glioblastoma multiforme, Radiotherapy, cell line, U87MG, dose rates, cell viability, MTTResumen
Glioblastoma multiforme is a tumor that affects glial cells and is common in humans, being the most aggressive of gliomas. Patients, after diagnosis, have an average survival of just over a year, even when undergoing standard treatment. Given the low estimated survival of patients with this type of tumor, the objective of the study is to investigate the contribution of dose rate in radiotherapeutic treatment using a human glioblastoma cell line called U87MG, through the MTT (brometo de 3-[4,5-dimetiltiazol-2-il]-2,5-difenil tetrazólio) cell viability assay. Three dose rates were tested, including 400 cGy/min which is used clinically in patients, as well as 1.400 and 3.300 cGy/min from a clinical linear accelerator. Sterile culture plates with U87MG cells were irradiated, then, manipulated in the laboratory for the execution of the cell viability assay. The irradiated plates showed lower cell viability than the non-irradiated group, but there was no significant difference in viability among the different tested dose rates.
Descargas
Referencias
[1] ALIFIERIS, Constantinos; TRAFALIS, Dimitrios T. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacology & therapeutics, v. 152, p. 63-82, 2015. DOI: https://doi.org/10.1016/j.pharmthera.2015.05.005
[2] WEN, Patrick Y.; KESARI, Santosh. Malignant gliomas in adults. New England Journal of Medicine, v. 359, n. 5, p. 492-507, 2008. DOI: https://doi.org/10.1056/NEJMra0708126
[3] CLOUGHESY, Timothy F.; CAVENEE, Webster K.; MISCHEL, Paul S. Glioblastoma: from molecular pathology to targeted treatment. Annual review of pathology: mechanisms of disease, v. 9, n. 1, p. 1-25, 2014. DOI: https://doi.org/10.1146/annurev-pathol-011110-130324
[4] BARANI, Igor J.; LARSON, David A. Radiation therapy of glioblastoma. Current understanding and treatment of gliomas, p. 49-73, 2015. DOI: https://doi.org/10.1007/978-3-319-12048-5_4
[5] CHÉDEVILLE, Agathe L.; MADUREIRA, Patricia A. The role of hypoxia in glioblastoma radiotherapy resistance. Cancers, v. 13, n. 3, p. 542, 2021. DOI: https://doi.org/10.3390/cancers13030542
[6] GHASEMI, Mahshid et al. The MTT assay: utility, limitations, pitfalls, and interpretation in bulk and single-cell analysis. International journal of molecular sciences, v. 22, n. 23, p. 12827, 2021. DOI: https://doi.org/10.3390/ijms222312827
Descargas
Publicado
Número
Sección
Categorías
Licencia
Derechos de autor 2025 Arthur Rocha, Ruy Rayol Neto, Debora Assis Carneiro, Delano Valdivino Batista, Luiz Antonio Ribeiro da Rosa, Mariana Paranhos Stelling, Simone Coutinho Cardoso
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Licencia: los artículos de BJRS tienen una licencia internacional Creative Commons Attribution 4.0, que permite el uso, el intercambio, la adaptación, la distribución y la reproducción en cualquier medio o formato, siempre que se otorgue el crédito correspondiente al autor o autores originales y a la fuente, proporcione un enlace a la licencia Creative Commons e indique si se realizaron cambios. Las imágenes u otros materiales de terceros en el artículo están incluidos en la licencia Creative Commons del artículo, a menos que se indique lo contrario en una línea de crédito al material. Si el material no está incluido en la licencia Creative Commons del artículo y su uso previsto no está permitido por la regulación legal o excede el uso permitido, el autor deberá obtener el permiso directamente del titular de los derechos de autor. Para ver una copia de esta licencia, visite http://creativecommons.org/licenses/by/4.0/
